Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 5, 2007

Resverlogix Initiates Alzheimer's Research Program

  • Resverlogix initiated a research program dedicated to ApoA-I production and testing its therapeutic potential for disorders that affect cognitive function, such as Alzheimer's Disease.

    Epidemiological and mechanistic evidence indicate a link between low ApoA-I/HDL and neurodegenerative diseases. Resverlogix says it has molecules that are potent and selective in raising plasma ApoA-I/HDL by increasing ApoA-I production, which may beneficially impact AD. The Alzheimer's program will be developed by RVX Therapeutics, a wholly owned subsidiary of Resverlogix, and does not signal a change in any other processes or programs currently underway at Resverlogix.

    "There remains a great unmet need in this therapeutic area," stated Jan Johansson, senior vp of clinical affairs at Resverlogix. "The growing body of evidence illustrating the ApoA-I/HDL protective role in neurodegenerative diseases makes a compelling argument for our lead ApoA-I technology, NexVas PR."


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »